IncobotulinumtoxinA与OnabotulinumtoxinA治疗膀胱过度活动症的非劣效随机试验
这项单盲随机非劣效试验比较了膀胱逼尿肌内注射100单位incobotulinumtoxinA与onabotulinumtoxinA治疗特发性膀胱过度活动症的效果。主要终点为基线至术后2-6周急迫性尿失禁发作平均数的变化,结果显示两组差值0.41(90%CI -0.88至1.71),达到预设非劣效界值-1,结论为incobotulinumtoxinA不劣于onabotulinumtoxinA。
要点
- IncobotulinumtoxinA 100U逼尿肌注射在减少急迫性尿失禁方面不劣于OnabotulinumtoxinA 100U。
- 两组PGI-I评分有差异,但回答「非常好」和「好很多」的比例相似。
- 其他次要结局及不良事件无统计学显著差异。
核心结论
- 逼尿肌内注射incobotulinumtoxinA在治疗特发性膀胱过度活动症方面不劣于onabotulinumtoxinA,并提供更纯、成本效益更高且物流更方便的替代选择。
研究设计与样本
- 单盲、随机、非劣效试验,共分析59名参与者(incobotulinumtoxinA组29人,onabotulinumtoxinA组30人),参与者接受逼尿肌内注射100单位incobotulinumtoxinA或100单位onabotulinumtoxinA。
主要发现
- 从基线至治疗后2-6周,incobotulinumtoxinA组与onabotulinumtoxinA组急迫性尿失禁发作平均减少量的差值为0.41(90%CI -0.88至1.71),达到预设非劣效界值-1。
- incobotulinumtoxinA组日间排尿次数平均减少0.97±2.54(基线7.28±2.77),onabotulinumtoxinA组减少2.97±4.74(基线9.57±5.61),P<.05。
- 患者整体改善印象评分两组间有显著差异(incobotulinumtoxinA组2.57±1.34,onabotulinumtoxinA组1.93±0.83,P<.05),但回答「非常好」和「好很多」的参与者比例相似(incobotulinumtoxinA组64%,onabotulinumtoxinA组71%)。
- 其他次要结局及不良事件两组间无统计学显著差异。
关键数值与推荐
- 非劣效界值预设为-1,主要终点差值0.41(90%CI -0.88至1.71)满足非劣效。
- onabotulinumtoxinA组绝经后参与者比例显著高于incobotulinumtoxinA组(80% vs 51.72%,P<.05)。
临床怎么用
- 对于特发性膀胱过度活动症患者,逼尿肌内注射incobotulinumtoxinA 100单位可作为onabotulinumtoxinA的替代方案,且可能更具成本效益和物流便利性。
局限性
- 样本量较小(共59人),单盲设计,随访时间较短(2-6周),且两组绝经后参与者比例存在显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of incobotulinumtoxinA to onabotulinumtoxinA for the treatment of idiopathic overactive bladder syndrome. METHODS: This study is a single-blinded, randomized, non-inferiority trial. Participants received intradetrusor injections of either 100 units of incobotulinumtoxinA or 100 units of onabotulinumtoxinA. The primary outcome was measured as a change in the mean number of urgency urinary incontinence episodes from baseline to 2-6 weeks post-procedure. RESULTS: Data from 59 participants were analyzed (29 incobotulinumtoxinA, 30 onabotulinumtoxinA). Most participants were between 40 and 59 years of age and postmenopausal. There were significantly more postmenopausal participants in the onabotulinumtoxinA group (51.72% incobotulinumtoxinA, 80% onabotulinumtoxinA, P<.05). Comparing incobotulinumtoxinA to onabotulinumtoxinA, the difference in mean reduction of urgency urinary incontinence episodes from baseline to 2-6 weeks post-treatment was 0.41 (90% confidence interval -0.88 to 1.71), meeting the predetermined non-inferiority margin of -1. The mean daytime voids decreased by 0.97 ± 2.54 from baseline of 7.28 ± 2.77 in the incobotulinumtoxinA group, and by 2.97 ± 4.74 from baseline of 9.57 ± 5.61 in the onabotulinumtoxinA group (P<.05). The Patient Global Impression of Improvement scores were significantly different between the 2 groups (2.57 ± 1.34 IncobotulinumtoxinA, 1.93 ± 0.83 OnabotulinumtoxinA [P<.05]). However, the number of participants answering "very much better" and "much better" was similar between the groups (64% IncobotulinumtoxinA, 71% OnabotulinumtoxinA). There was no statistically significant difference in other secondary outcomes or with adverse events between the 2 groups. CONCLUSION: Intradetrusor incobotulinumtoxinA was found to be non-inferior to onabotulinumtoxinA in the treatment of idiopathic overactive bladder syndrome and offers a more pure, cost-effective, and logistically convenient alternative.
引用
- Trikhacheva AS, Hamade SJ, Gisseman JD, et al. IncobotulinumtoxinA Versus OnabotulinumtoxinA for Treatment of Overactive Bladder Syndrome: A Randomized Single-blinded Non-inferiority Trial. Urology. 2026. PMID: 41933558. doi:10.1016/j.urology.2026.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。